Some mentioned “medical revolution” for patients with cystic fibrosis. A year after its reimbursement was approved, Kaftrio has largely delivered on its promise. The 2021 report of the French Cystic Fibrosis Registry, the results of which were published on Thursday September 15, highlights the impressive real-life beneficial effects of this innovative treatment targeting the most common rare disease in Europe, a genetic pathology that secretes excess. mucus and significantly reduces life span. “The evolution is positive on all clinical indicators, and this trend seems to be confirmed in 2022, with an increase in the number of prescriptions.”, rejoices Paola de Carli, director of the research department of Vaincre la mucoviscidose. The patient association maintains and updates the epidemiological surveillance of more than 7,500 people (that is, almost all French patients).
Produced by the American laboratory Vertex Pharmaceuticals…
Source: Le Figaro
